Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast Inflammatory CarcinomaInvasive Breast CarcinomaPrognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05177796
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
- Conditions
- Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Stage IV MelanomaLocally Advanced MelanomaPathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Interventions
- Drug: CyclophosphamideDrug: FludarabineBiological: LifileucelBiological: PembrolizumabProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Richard Wu
- Target Recruit Count
- 2
- Registration Number
- NCT05176470
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
- Conditions
- T-lymphoblastic LymphomaAcute Biphenotypic LeukemiaAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaAcute LeukemiaAcute Undifferentiated LeukemiaMyelodysplastic Syndromes
- Interventions
- Drug: CyclophosphamideDrug: FludarabineRadiation: Total Body IrradiationDrug: BusulfanDrug: MesnaDrug: SirolimusDrug: Mycophenolate MofetilDrug: FilgrastimProcedure: Bone Marrow Transplant
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Ossium Health, Inc.
- Registration Number
- NCT05170828
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
- Conditions
- B Acute Lymphoblastic LeukemiaPh-Like Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT05157971
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
- Conditions
- LymphomaNeoplasmsLymphoma, Mantle-CellNeoplasms by Histologic TypeLymphoproliferative Disorders
- Interventions
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
- Target Recruit Count
- 68
- Registration Number
- NCT05155215
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG
- Conditions
- MDS/MPNGraft Vs Host DiseaseCMMLPeripheral Blood Stem Cell TransplantationAMLMDS
- Interventions
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- DKMS gemeinnützige GmbH
- Target Recruit Count
- 640
- Registration Number
- NCT05153226
- Locations
- 🇩🇪
Universitätsklinikum des Saarlandes, Homburg, Germany
🇩🇪Uniklinik RWTH Aachen, Aachen, Germany
🇩🇪Univeristätsklinikum Augsburg, Augsburg, Germany
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
- Conditions
- Neoplasms, Plasma CellHematologic DiseasesMultiple MyelomaRenal ImpairmentBlood Protein DisordersParaproteinemiasNeoplasms by Histologic TypeNeoplasms
- Interventions
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Hellenic Society of Hematology
- Target Recruit Count
- 51
- Registration Number
- NCT05147493
- Locations
- 🇬🇷
Anticancer Oncology Hospital of Athens "Agios Savvas", Athens, Greece
🇬🇷University General Hospital of Ioannina, Ioannina, Greece
🇬🇷Anticancer Hospital of Thessaloniki "Theageneio", Thessaloniki, Greece
Neoadjuvant Treatment of Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- National Institute of Oncology, Hungary
- Target Recruit Count
- 300
- Registration Number
- NCT05131893
- Locations
- 🇭🇺
National Institute of Oncolgy, Budapest, Hungary
Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL
- Conditions
- Lymphoma Leukemia
- Interventions
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT05114837
- Locations
- 🇺🇸
Masonic Cancer Center - University of Minnesota, Minneapolis, Minnesota, United States
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
- Conditions
- Myeloid MalignanciesAcute Myeloid LeukemiaChronic Myeloid LeukemiaMyelodysplastic Syndrome
- Interventions
- Drug: MesnaDrug: Fludarabine phosphateDrug: CyclophosphamideDrug: MelphalanDrug: FilgrastimDrug: TacrolimusDrug: Mycophenolate mofetilDrug: Total Body Irradiation One Dose
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05115630
- Locations
- 🇺🇸
M D Anderson Caner Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.